Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-402-9 | CAS number: 120-51-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
The screening study for reproductive / developmental toxicity and the extended one-generation reproductive toxicity study are waived.
Data are available for a developmental toxicity investigation of dietary administration of benzyl benzoate to pregnant rats at maximum tolerated exposures through gestation and also through gestation and continuing to 21 days post-partum. A reproductive toxicity/developmental screening study is therefore not required.
The extended one-generation reproductive toxicity study does not need to be conducted because there are no results from available repeated dose toxicity studies that indicate adverse effects on reproductive organs or tissues, or reveal other concerns in relation with reproductive toxicity.
Effect on fertility: via oral route
- Endpoint conclusion:
- no study available
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Short description of key information:
No data are available.
Effects on developmental toxicity
Description of key information
Administration of benzyl benzoate in diet up to inclusion levels of 194.3 mg/kg per rat/d (0 ca. 646 mg/kg bw/d) resulted in no adverse maternal effects and no biologically significant or dose-dependent effects in foetuses and neonates maintained to postpartum day 21.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Published study of non-standard design but considered to be scientifcally sound and adequate for the assessment of developmental toxicity.
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Pregnant Wistar rats were given commercial powdered diets supplemented with 0.04 or 1.0% benzyl benzoate (BB) from day 0 of gestation to day 21 post-parturition. Various parental reproductive indices and developmental indices, in utero and post-partum were evaluated.
- GLP compliance:
- not specified
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: No data
- Age at study initiation: ~6 weeks
- Weight at study initiation: no data
- Fasting period before study: no data
- Housing: no data
- Diet (e.g. ad libitum): Oriental powdered feed M. The test material was administerd by dietary admixture at two inclusion levels, diet given ad libitum
- Water (e.g. ad libitum): tap water ad libitum
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23-25
- Humidity (%): 45-55
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): no details
IN-LIFE DATES: From: no data;n To: no data. Study findings published in 1981. - Route of administration:
- oral: feed
- Vehicle:
- other: powdered diet
- Details on exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): no details
- Mixing appropriate amounts with (Type of food): Dose levels were selected on basis of a preliminary study (data not reported here), the maximum tolerated dose of benzyl benzoate was 1% dietary inclusion. The lower dose was 0.04%. - Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- No data
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: overnight, from pro-oestrous to oestrous.
- Proof of pregnancy: time sperm observed in the vaginal smear was referred to as Day 0 of pregnancy/gestation.
A vaginal smear was taken from nulliparous females ad examined microscopically to determine stage of oestrous cycling. The females were pair housed with a single male over night from the estimated pro-oestrous to oestrous stages. A second smear was examined each morning after overnight pairing and if sperm were observed in the smear then that was designated day 0 of pregnancy. - Duration of treatment / exposure:
- Dams had access to treated diets from Gestation Day 0 to Day 20 and from Day 0 to Day 21 post-partum.
- Frequency of treatment:
- daily via treated diet
- Duration of test:
- Gestation day 0 -20
Gestation day 0 to day 21 post partum - No. of animals per sex per dose:
- 21 females per group
One group of 21 females was split - 14 animals were terminated at Day 20 and 7 retained for a 21 day post-partum phase. - Control animals:
- yes, plain diet
- Details on study design:
- No further details available
- Maternal examinations:
- Pre-partum Study phase
General clinical observations of the condition of pregnant animals were made daily together with body weight recordings and recording of treated or control diet consumption.
Dams were sacrificed on Day 20 of pregnancy by ether anaesthesia, the abdomen was immediately opened, the uterus was removed, the number of implantation sites, number of resorptions and number of foetal deaths were determined, the body weight of live foetuses was measured and the gender and presence of external abnormalities was investigated.
In addition, the number of corpora lutea in the maternal ovaries were determined.
Post-partum Study:
Pregnant females were allowed to give birth naturally and the number of live offspring and number of dead offspring were determined immediately after confirming birth had taken place. Neonates were allowed to suckle from dams until Day 21 postpartum and, during this time, the growth differentiation conditions such as the gender, the number of live newborn, presence of external abnormalities, pinnae detachment, emergence of hair and opening of eyelids as well as general conditions were observed. Body weights were measured 7, 14 and 21 days postpartum. Surviving neonates were sacrificed by ether anaesthesia up to Day 21 post-partum and a skeletal examination was conducted using soft X rays. In addition, dams were sacrificed in the same way and the number of implantation sites was investigated. - Ovaries and uterine content:
- Dams were sacrificed on Day 20 of pregnancy by ether anaesthesia, the abdomen was immediately opened, the uterus was removed, the number of implantation sites, number of resorptions and number of foetal deaths were determined, the body weight of live foetuses was measured and the gender and presence of external abnormalities was investigated.
In addition, the number of corpora lutea in the maternal ovaries were determined. - Fetal examinations:
For the pre-partum treatment groups, skeletal staining was conducted in approximately half the live foetuses using Alizarin red S according to the method of Dawson following fixation in 90% ethanol. The presence of skeletal abnormalities and the degree of ossification were investigated. The remaining foetuses had abnormalities in internal organs determined according to the method of Wilson, following fixation in Bouin's solution.
For the postpartum phase, pregnant females were allowed to give birth naturally and the number of live offspring and number of dead offspring were determined immediately after confirming birth had taken place.
The neonates were raised naturally and allowed to suckle from dams until Day 21 postpartum. During this period growth differentiation conditions were monitored - gender, number of live newborn, presence of external abnormalities, pinnae detachment, emergence of hair and opening of eyelids. The general condition of the pups was also observed through this period. Pup body weights were recorded 7, 14 and 21 days postpartum.
Surviving neonates were sacrificed by ether anaesthesia on Day 21 postpartum and a skeletal examination was conducted using soft X rays. The dams were also sacrificed on Day 21 and the number of implantation sites was determined.- Statistics:
- Significant differences between the control group and administration groups were investigated using the χ2 test, t-test or the rank sum test. Furthermore, data handling was conducted with reference to the standard method in 'The Joint Parallel Study Relating to Teratogenicity of LAS by The Ministry of Health, Labour and Welfare 1974 group'.
- Historical control data:
- no information available
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
Benzyl benzoate effects on dams in the pre-partum phase.
Benzyl benzoate ingestion via treated diet at 0.04 and 1% had little effect on body weight progression for pregnant female rats. The daily food intake for treated and control groups showed no marked variations between Gestation days 0 and 20.
Benzyl benzoate ingested was calculated in terms of mg/rat over the entire period of gestation (Day 0-20). The low group (0.04%) mean total consumption was 153.4 mg/rat, equivalent to 7.7 mg benzyl benzoate per day. For the high dose group (1%), total consumption was 3886.7 mg/rat and 194.3 mg per day.
There were no noteworthy changes in the general conditions for either treated groups over the gestation period. Benzyl benzoate caused no macroscopic changes attributable to treatment. - Dose descriptor:
- dose level: 194.3 mg/rat per day.
- Remarks on result:
- other: no effect on pregnant females
- Abnormalities:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Benzyl benzoate effects on foetuses
Foetal effects on Day 20 of pregnancy are presented in Tables 2 and 3 attached.
There were few differences between control and treated groups in relation to the numbers of corpora lutea incidence of pregnancy, the number of implantations, the number of foetal deaths (either early stage or late stage), the number of live foetuses, the pup sex ratio and the body weights of live foetuses.
From the external observations on Gestation Day 20, one foetus in the control group had an umbilical hernia. In the benzyl benzoate 1% treated groups there was one foetus each with mandibular defects, absence of a tongue or a cleft palate but there was no significant difference in incidence compared with controls.
No effects were apparent in the low dose treated group.
the skeletal observations revealed no malformations in any group. The occurrence of foetuses with incomplete ossification of sternebral centres decreased in the high dose group, benzy benzoate 1.0%. The visceral observations revealed one foetus in the high dose group, 1% benzyl benzoate had bilateral heterotaxiabut there was no significant difference in incidence of findings between treated and control groups.
Other abnormalities noted but not showing any treatment relationship, or statistically significant difference in incidence, included dilation of the renal pelvis (seen in one foetus in the low dose 0.04% benzyl benzoate group), dilation of the renal pelvis (two foetuses) and bisection of the apex (one foetus) were observed in the high dose group, 1% benzyl benzoate.
Effects on neonates during post-partum phase
Neonate body weights for the benzyl benzoate groups a small suppression of weight gain and by Day 14 both male and female pups from treated dams had slightly lower bodyweight than controls and a similar effect was also present on day 21 although the effect was not dose dependent. No changes of note in general condition occurred during the 21 day post-partum phase for any group.
Postnatal growth at parturition and for the neonates is presented in Table 4, (attached below). There were no biologically significant differences in the pup indices between any group in the gestation period. The number of implantations, the number of live offspring, the number of dead offspring, pup sex ratio, suckling rate and growth differentiation were similar for all groups. No external or skeletal abnormalities were seen in any of the groups - Dose descriptor:
- dose level: 194.3 mg/rat per day.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- No evidence of teratogenicity or developmental toxicity was observed under the conditions of this assay.
- Executive summary:
In this study, pregnant female rats were administered benzyl benzoate throughout gestation, with treatment continuing to Day 21 post-partum in some animals. Benzyl benzoate administered in diet to pregnant rats at inclusion levels of 0.04% and 1.0% . The effects of benzyl benzoate administration to the pregnant females, on foetuses and neonates were examined.
Benzyl benzoate administration had little effect on foetuses and neonates and no teratogenic effects of benzyl benzoate were evident.
Reference
Table 1 Food intake and amount of benzyl benzoate (BB) ingested for pregnant rats administered BB in diet
|
Control |
BB 0.04% |
BB 1.0% |
Bodyweight (g) |
|
|
|
Gestation Day 0 |
267 |
274 |
274 |
Gestation Day 20 |
366 |
378 |
377 |
Food intake (g/rat) |
|
|
|
Total (GD 0-20) |
365 |
384 |
389 |
Per day |
18.3 |
19.2 |
19.3 |
BB ingested (mg/rat) |
|
|
|
Total (GD 0-20) |
0 |
153.4 |
3886.7 |
Per day |
0 |
7.7 |
194.3 |
Table 2 Effect of dietary BB given to pregnant rats on the foetuses
|
Control |
BB 0.04% |
BB 1.0% |
Number of females inseminated |
20 |
19 |
22 |
Mean number of corpora lutea |
202 |
201 |
202 |
Mean number of implants |
175 |
175 |
167 |
Number of dead fetuses (early) [%] |
26 [16.3] |
25 [13.0] |
19 [11.2] |
Mean number of live fetuses |
149 |
150 |
147 |
Sex ratio (male:female pups) |
1.13 [79/70] |
1.00 [75/75] |
1.13 [78/69] |
Mean bodyweight of live fetuses Male |
3.90 |
4.03 |
3.98 |
Table 3 External, skeletal and visceral observations of fetuses from dams fed BB in diet
|
Control |
BB 0.04% |
BB 1.0% |
External observations |
|
|
|
Number of foetuses examined |
149 |
150 |
147 |
Number of foetuses with malformations (%) |
1 (1.0) |
0 |
1 (1.8) |
Malformation type (no. of fetuses affected) |
Umbilical hernia (1) |
-- |
Submaxilla defect (1) |
Skeletal observations |
|
|
|
Number of foetuses examined |
82 |
82 |
79 |
Number of foetuses with malformations |
0 |
0 |
0 |
Number of foetuses with variations (%) |
|
|
|
Asymmetry of sternebrae |
2 (3.0) |
1 (1.0) |
2 (2.2) |
Cervical rib |
8 (7.3) |
6 (6.7) |
3 (3.9) |
Lumbar rib |
1 (1.2) |
1 (0.9) |
0 |
Split or bifurcation of 1stor 2ndcervical vertebral arch |
0 |
0 |
0 |
Extra lumbar vertebra (L7) |
1 (1.2) |
0 |
0 |
Separation of thoracic vertebral centra |
1 (1.2) |
0 |
0 |
Degree of ossification |
|
|
|
Number of foetuses with incomplete sternebrae (%) |
27 (29.4) |
28 (36.3) |
15 (18.6*) |
Mean number of proximal and middle phalanges forepaw |
5.8 |
5.4 |
5.6 |
Mean number of sacral and caudal vertebrae |
7.9 |
7.8 |
8.0 |
|
|
|
|
Visceral observations |
|
|
|
Number of foetuses examined |
67 |
68 |
68 |
Number of foetuses with malformations (%) |
0 |
0 |
1 (1.2) |
Type (number of foetuses) |
-- |
-- |
Heteroataxia (1) |
Number of foetuses with other anomalies (%) |
0 |
1 (1.2) |
3 (3.8) |
Type (number of foetuses) |
-- |
Dilatation of renal pelvis (1) |
Dilatation of renal pelvis (2) Bifid apex of heart (1) |
Table 4 Postnatal observations for offspring from dams fed BB in diet
|
Control |
BB 0.04% |
BB 1.0% |
Number of females inseminated |
11 |
13 |
13 |
Mean duration of gestation (days) |
21.7 |
22.0 |
21.7 |
Mean number of implants |
79 |
71 |
81 |
Mean number of live newborns |
68 |
61 |
74 |
Mean number of dead newborns |
1 |
0 |
0 |
Sex ratio (male/female |
1.3 (39/30) |
1.18 (33/28 |
1.11 (39/35) |
Viability at weaning, % ## |
83.1 |
92.1 |
88.5 |
External differentiation (mean no. days) detachment of ears |
2.5 |
2.3 |
2.8 |
Number of pups with external anomalies |
0 |
0 |
0 |
Number of pups with skeletal anomalies |
0 |
0 |
0 |
## No of live pups at 21 days postpartum / no of live pups at birth x 100
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 646 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- A non-standard study of developmental toxicity in the rat is available.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Justification for selection of Effect on developmental toxicity: via oral route:
Only one study is available for this endpoint.
Justification for classification or non-classification
According to CLP classification criteria (Regulation (EC) No 1272/2008) a classification is not justified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)